Brief: Alligator Bioscience Announces Positive Mitazalimab Optimize-1 Phase 2 Results
Jan 29 (Reuters) - Alligator Bioscience AB ATORX.ST :
* ANNOUNCES POSITIVE MITAZALIMAB OPTIMIZE-1 PHASE 2 RESULTS
MEETING PRIMARY ENDPOINT AND DEMONSTRATING CLINICALLY RELEVANT
SURVIVAL BENEFITS IN 1ST LINE PANCREATIC CANCER
* DISCUSSIONS WITH FDA CONFIRM A CLEAR APPROVAL PATHWAY WITH
PHASE
3 REGISTRATION STUDY ON TRACK TO START IN EARLY 2025
Source text for Eikon: ID:nMFN3c3NSL
Further company coverage: ATORX.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Alligator Bioscience AB
See all newsBrief: Alligator Bioscience Q1 Net Loss SEK 1.4 Million
Sweden's Alligator Bioscience posts Q1 net profit, narrows operating loss
Brief: Alligator Bioscience Q1 EBIT SEK -17.8 Million
Brief: Alligator Bioscience Signs LoI With Unicancer For Phase 3 Mitazalimab Development
Brief: Exercise Of Warrants Brings Alligator Bioscience Net Proceeds Of SEK 12 Mln